Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.
+ 2 more risks
Solid track record and good value.
Share Price & News
How has Horizon Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HPR's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HPR exceeded the German Pharmaceuticals industry which returned 8.1% over the past year.
Return vs Market: HPR exceeded the German Market which returned 3.8% over the past year.
Price Volatility Vs. Market
How volatile is Horizon Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Horizon Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HPR (€53.27) is trading below our estimate of fair value (€103.17)
Significantly Below Fair Value: HPR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HPR is good value based on its PE Ratio (19.3x) compared to the DE Pharmaceuticals industry average (21.1x).
PE vs Market: HPR is good value based on its PE Ratio (19.3x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: HPR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: HPR is overvalued based on its PB Ratio (5.3x) compared to the DE Pharmaceuticals industry average (3.1x).
How is Horizon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HPR's earnings are forecast to decline over the next 3 years (-40.7% per year).
Earnings vs Market: HPR's earnings are forecast to decline over the next 3 years (-40.7% per year).
High Growth Earnings: HPR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: HPR's revenue (16.6% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: HPR's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HPR's Return on Equity is forecast to be high in 3 years time (30.5%)
How has Horizon Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HPR has a large one-off loss of $65.3M impacting its March 31 2020 financial results.
Growing Profit Margin: HPR's current net profit margins (43.1%) are higher than last year (6.1%).
Past Earnings Growth Analysis
Earnings Trend: HPR has become profitable over the past 5 years, growing earnings by 31.1% per year.
Accelerating Growth: HPR's earnings growth over the past year (663%) exceeds its 5-year average (31.1% per year).
Earnings vs Industry: HPR earnings growth over the past year (663%) exceeded the Pharmaceuticals industry 15.8%.
Return on Equity
High ROE: HPR's Return on Equity (27.1%) is considered high.
How is Horizon Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: HPR's short term assets ($1.4B) exceed its short term liabilities ($592.4M).
Long Term Liabilities: HPR's short term assets ($1.4B) do not cover its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: HPR's debt to equity ratio (62.1%) is considered high.
Reducing Debt: HPR's debt to equity ratio has reduced from 85.9% to 62.1% over the past 5 years.
Debt Coverage: HPR's debt is well covered by operating cash flow (22.6%).
Interest Coverage: HPR's interest payments on its debt are not well covered by EBIT (1.6x coverage).
What is Horizon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HPR's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Walbert (53 yo)
Mr. Timothy P. Walbert, also known as Tim, serves as Chairman of the Board at Exicure, Inc. since April 2020. Mr. Walbert serves as Lead Independent Director at Assertio Holdings, Inc. from May 19, 2020. M ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD13.87M) is above average for companies of similar size in the German market ($USD5.26M).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||5.83yrs||US$4.44m||0.069% |
|Executive VP & Chief Administrative Officer||0.58yr||US$4.66m||0.093% |
|Executive VP & Chief Commercial Officer||no data||US$4.06m||0.022% |
|Chief Accounting Officer & Senior VP||5.67yrs||no data||0.018% |
|Senior Vice President of Investor Relations||no data||no data||no data|
|Executive VP & General Counsel||5.25yrs||no data||0.019% |
|Chief Compliance Officer & VP||5.25yrs||no data||no data|
|Executive VP of Corporate Affairs & Chief Communications Officer||4.67yrs||no data||0.018% |
|Executive VP & Chief Human Resources Officer||2.92yrs||US$2.31m||0.019% |
|Executive VP & Chief Medical Officer||no data||US$916.28k||0.15% |
|Senior Vice President of Business Development & Alliance Management||7.42yrs||no data||no data|
Experienced Management: HPR's management team is seasoned and experienced (5.3 years average tenure).
|Lead Independent Director||8yrs||US$524.03k||0.033% |
|Independent Director||5.92yrs||US$502.76k||0.035% |
|Independent Director||8.42yrs||US$518.83k||0.021% |
|Independent Director||6.33yrs||US$515.22k||0.040% |
|Independent Director||3yrs||US$507.24k||0.015% |
|Independent Director||1yr||US$341.79k||0.0038% |
|Independent Director||3yrs||US$494.61k||0.016% |
Experienced Board: HPR's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HPR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.
Horizon Therapeutics Public Limited Company's company bio, employee growth, exchange listings and data sources
- Name: Horizon Therapeutics Public Limited Company
- Ticker: HPR
- Exchange: DB
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$11.674b
- Listing Market Cap: US$9.868b
- Shares outstanding: 190.78m
- Website: https://www.horizontherapeutics.com
Number of Employees
- Horizon Therapeutics Public Limited Company
- Connaught House
- 1st Floor
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HZNP||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2011|
|HPR||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2011|
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic disease ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/02 21:56|
|End of Day Share Price||2020/07/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.